Transdermal Clonidine for Smoking Cessation: A Double-Blind Randomized Dose-Response Study

A 4-week trial tested the effects of 4 doses (placebo, 0.1 mg/d, 0.2 mg/d, and 0.3 mg/d) of transdermal clonidine on smoking cessation and nicotine withdrawal. After a 1-week baseline, smokers ( N = 72) started the drug and tried to quit by Week 3. Significantly fewer smokers who received a placebo...

Full description

Saved in:
Bibliographic Details
Published in:Experimental and clinical psychopharmacology 1996-08, Vol.4 (3), p.285-291
Main Authors: Niaura, Raymond, Brown, Richard A, Goldstein, Michael G, Murphy, Joseph K, Abrams, David B
Format: Article
Language:English
Subjects:
Clonidine
Drug Therapy
Female
Human
Male
Nicotine Withdrawal
Smoking Cessation
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A 4-week trial tested the effects of 4 doses (placebo, 0.1 mg/d, 0.2 mg/d, and 0.3 mg/d) of transdermal clonidine on smoking cessation and nicotine withdrawal. After a 1-week baseline, smokers ( N = 72) started the drug and tried to quit by Week 3. Significantly fewer smokers who received a placebo were abstinent at 5 days after quitting as compared with smokers who received clonidine at any dose (19% vs. 57%, respectively, p = .007). Blood clonidine concentration interacted with nicotine dependence ( p < .05): High-dependence smokers who achieved higher blood clonidine concentrations survived longer before smoking a cigarette after quitting, as compared with high-dependence smokers who achieved lower blood levels. Changes from baseline in heart rate, blood pressure, appetite, irritability, and anxiety were inversely associated with blood clonidine concentrations.
ISSN:1064-1297
1936-2293
DOI:10.1037/1064-1297.4.3.285